Galapagos NV (GLPG)

63.26
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    60.77/67.38
  • Day's Range:
    63.00 - 63.26

GLPG Overview

Prev. Close
64.07
Day's Range
63-63.26
Revenue
-
Open
63
52 wk Range
57.79-189.3
EPS
-
Volume
0
Market Cap
4.03B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
311
P/E Ratio
-
Beta
-
1-Year Change
-64.03%
Shares Outstanding
-
Next Earnings Date
Aug 05, 2021
What is your sentiment on Galapagos NV?
or
Vote to see community's results!

Galapagos NV News

Galapagos NV Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsSellSellSellSellSell
SummaryStrong SellStrong SellStrong SellStrong SellSell

Galapagos NV Company Profile

Galapagos NV Company Profile

Employees
1328

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren’s syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company’s clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Read More
  • Update: it looks like it broke out of the falling wedge. The odds of this going higher are better now
    0
    • nice job on profit! now a beautiful takeover. I'm guessing Pharming Group
      1
      • no earnings today? or they failed even on that???
        0
        • 45$ is a good entry point
          2
          • This trash is going to 32 Euro. Have fun!
            3
            • ooh, u bougt in too high?
              1
            • 0
          • Ready for takeover?!
            1
            • It makes for a good takeover now!
              0
              • Verkopen die boel - teveel vraagtekens. Wat ben je met hoop cash als je bedrijf een holle doos is...
                2
                • Geen enkel medicijn meer op de plank wat verkoopbaar is.
                  3
                  • wel 5 miljard cash waarmee ze overnames kunnen doen 😏
                    1
                • guys, any good news that could wake up this one? I had it on red when it went downs 18.5% in a day.... is long way ...
                  0
                  • RIP
                    2
                • Enig nieuws omtrent de voordracht en reacties op conference bij JP morgan?
                  0
                  • zelfde koers als vorig jaar , 1 groot verschil is dat ze nu wel omzet draaien. ik zie dit aandeel niet verder zakken.
                    0
                    • Ze kunnen dus nog dieper zakken -18.72% weer
                      0
                    • 66.10 nu
                      0
                    • 58 nu
                      0
                  • Zijn alle vertrouwen kwijt in galapagos. Zal een lange weg zijn voor men er terug vertrouwen in krijgt. Als de ceo ook aandelen verkoopt voor het aandeel 20% zakt en dan terug koopt
                    1
                    • waardeloos management. Niks communiceren omtrent Halloweenmeeting. Dan zelf cashen ondanks het feit dat aandelen 40% van ATH stond. En nu instappen. Hoop echt dat de VEB hier vol achter aan gaan. Onno en zijn oplichtersbende
                      1
                    • @ Tony: dat heb ik eigenhandig meer CEO's zien doen hoor; Je zou nog verschieten wie
                      0
                  • bought at 122, long term goal (+-1y) 150
                    1
                    • You should sell it when you can and invest in the American stock market. There is too much regulation here that keeps the market down. Stocks like these go up big on speculation, but decline a lot on failed medicine.
                      1
                    • Check out Nio, Palantir technologies for huge profits or Tesla for a safer bet. The future is in full self drive. Also check out what Cathy Wood says. Everything she invests in turns to gold.
                      0
                    • Long term goal
                      0
                  • What a POS!! It drops suddenly
                    0
                    • you must be new to this?
                      0
                  • Man this should recover back to 120-130 at least. It is still a reputable bio company
                    0
                    • so what was the reason of that deep..?Earnings looks like expected.. did company failed on some research ?
                      0
                      • one of their products did not get cleared by FDA
                        0
                    • what a scam this stock, never believes CEOs is the lesson
                      0
                      • Would buy the dip apply here? :D
                        0
                        • My God :o
                          0
                          • what a deep fall!
                            0
                            • Ouch
                              0
                              • small volume.
                                0
                                • Such random bs. While everything is green, this is red
                                  0
                                  • https://www.ema.europa.eu/en/medicines/human/summaries-opinion/jyseleca On 23 July 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Jyseleca, intended for the treatment of rheumatoid arthritis. The applicant for this medicinal product is Gilead Sciences Ireland UC. Jyseleca will be available as 100 mg and 200 mg film-coated tablets. The active substance of Jyseleca is filgotinib, an immunosuppressants (ATC code: L04AA45). Filgotinib is an adenosine triphosphate (ATP) competitive and reversible inhibitor of the Janus kinase (JAK) family.
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.